Literature DB >> 1989669

Photosensitising potency of structural analogues of benzoporphyrin derivative (BPD) in a mouse tumour model.

A M Richter1, E Waterfield, A K Jain, B Allison, E D Sternberg, D Dolphin, J G Levy.   

Abstract

The in vivo characteristics of four analogues of benzoporphyrin derivative (BPD) have been investigated. Biodistribution data obtained in DBA/2J mice with BPD-MA (monoacid ring A analogue) which had been tritiated or internally labelled with 14C showed that both labelled materials acted in an essentially identical manner during the period of study. Biodistribution and clearance studies showed that relative distribution in a variety of mouse tissues was similar for all BPD analogues. M1 tumour cells (rhabdomyosarcoma in DBA/2J mice) taken from tumours excised from animals treated 3 h earlier with BPD, and tested in vitro for photosensitivity provided evidence that significant levels of photosensitiser detected in tumour was both active and associated with tumour cells. The monoacid forms of BPD were found to be much more photodynamically active in this test than were the diacid analogues. The ability of the analogues to ablate tumours in mice by photodynamic therapy was also tested. Again, BPD-MA and BPD-MB proved to be measurably better than the diacid analogues. These findings are discussed in reference to structural and physical differences between the analogues.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1989669      PMCID: PMC1971633          DOI: 10.1038/bjc.1991.18

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  14 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  The plasma distribution of benzoporphyrin derivative and the effects of plasma lipoproteins on its biodistribution.

Authors:  B A Allison; P H Pritchard; A M Richter; J G Levy
Journal:  Photochem Photobiol       Date:  1990-09       Impact factor: 3.421

3.  Biodistribution of tritiated benzoporphyrin derivative (3H-BPD-MA), a new potent photosensitizer, in normal and tumor-bearing mice.

Authors:  A M Richter; S Cerruti-Sola; E D Sternberg; D Dolphin; J G Levy
Journal:  J Photochem Photobiol B       Date:  1990-04-15       Impact factor: 6.252

4.  Characterization of plasma lipoproteins separated and purified by agarose-column chromatography.

Authors:  L L Rudel; J A Lee; M D Morris; J M Felts
Journal:  Biochem J       Date:  1974-04       Impact factor: 3.857

5.  Chemistry of hematoporphyrin-derived photosensitizers.

Authors:  D Kessel; P Thompson; B Musselman; C K Chang
Journal:  Photochem Photobiol       Date:  1987-11       Impact factor: 3.421

6.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

7.  In vitro evaluation of phototoxic properties of four structurally related benzoporphyrin derivatives.

Authors:  A M Richter; E Waterfield; A K Jain; E D Sternberg; D Dolphin; J G Levy
Journal:  Photochem Photobiol       Date:  1990-09       Impact factor: 3.421

8.  Preliminary studies on a more effective phototoxic agent than hematoporphyrin.

Authors:  A M Richter; B Kelly; J Chow; D J Liu; G H Towers; D Dolphin; J G Levy
Journal:  J Natl Cancer Inst       Date:  1987-12       Impact factor: 13.506

9.  Distribution and elimination of Photofrin II in mice.

Authors:  D A Bellnier; Y K Ho; R K Pandey; J R Missert; T J Dougherty
Journal:  Photochem Photobiol       Date:  1989-08       Impact factor: 3.421

10.  Evidence for a major role of plasma lipoproteins as hematoporphyrin carriers in vivo.

Authors:  G Jori; M Beltramini; E Reddi; B Salvato; A Pagnan; L Ziron; L Tomio; T Tsanov
Journal:  Cancer Lett       Date:  1984-10       Impact factor: 8.679

View more
  16 in total

Review 1.  Treatment of subfoveal choroidal neovascularisation in age related macular degeneration: focus on clinical application of verteporfin photodynamic therapy.

Authors:  G Soubrane; N M Bressler
Journal:  Br J Ophthalmol       Date:  2001-04       Impact factor: 4.638

2.  Ascorbate enhances the toxicity of the photodynamic action of Verteporfin in HL-60 cells.

Authors:  Galina G Kramarenko; Werner W Wilke; Disha Dayal; Garry R Buettner; Freya Q Schafer
Journal:  Free Radic Biol Med       Date:  2006-01-19       Impact factor: 7.376

3.  Promotion of Proapoptotic Signals by Lysosomal Photodamage.

Authors:  David Kessel; John J Reiners
Journal:  Photochem Photobiol       Date:  2015-05-08       Impact factor: 3.421

Review 4.  Alternative therapies in exudative age related macular degeneration.

Authors:  N H Chong; A C Bird
Journal:  Br J Ophthalmol       Date:  1998-12       Impact factor: 4.638

5.  Apoptotic and autophagic responses to photodynamic therapy in 1c1c7 murine hepatoma cells.

Authors:  Michelle Andrzejak; Michael Price; David H Kessel
Journal:  Autophagy       Date:  2011-09-01       Impact factor: 16.016

Review 6.  Verteporfin.

Authors:  L J Scott; K L Goa
Journal:  Drugs Aging       Date:  2000-02       Impact factor: 3.923

Review 7.  Spotlight on verteporfin in subfoveal choroidal neovascularisation.

Authors:  Susan J Keam; Lesley J Scott; Monique P Curran
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

8.  Higher irradiance and photodynamic therapy for age-related macular degeneration (an AOS thesis).

Authors:  Joan W Miller
Journal:  Trans Am Ophthalmol Soc       Date:  2008

Review 9.  Verteporfin : a review of its use in the management of subfoveal choroidal neovascularisation.

Authors:  Susan J Keam; Lesley J Scott; Monique P Curran
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  The chorioretinal damage caused by different half parameters of photodynamic therapy in rabbits.

Authors:  Lan-Hsin Chuang; Yih-Shiou Hwang; Nan-Kai Wang; Yen-Po Chen; Laura Liu; Ling Yeung; Kuan-Jen Chen; Tun-Lu Chen; Wei-Chi Wu; Chi-Chun Lai
Journal:  J Ocul Pharmacol Ther       Date:  2014-06-20       Impact factor: 2.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.